C4 Therapeutics Inc CCCC.OQ CCCC.O is expected to show a fall in quarterly revenue when it reports results on November 3 (estimated) for the period ending September 30 2025
The Watertown Massachusetts-based company is expected to report a 59.1% decrease in revenue to $6.28 million from $15.36 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for C4 Therapeutics Inc is for a loss of 40 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for C4 Therapeutics Inc is $10.00, about 75.4% above its last closing price of $2.46
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.38 | -0.38 | -0.37 | Beat | 3.6 |
Mar. 31 2025 | -0.48 | -0.45 | -0.37 | Beat | 17.8 |
Dec. 31 2024 | -0.47 | -0.48 | -0.49 | Missed | -2.6 |
Sep. 30 2024 | -0.36 | -0.38 | -0.35 | Beat | 7.9 |
Jun. 30 2024 | -0.37 | -0.37 | -0.26 | Beat | 30 |
Mar. 31 2024 | -0.36 | -0.35 | -0.41 | Missed | -16.7 |
Dec. 31 2023 | -0.64 | -0.68 | -0.70 | Missed | -2.6 |
Sep. 30 2023 | -0.67 | -0.66 | -0.52 | Beat | 21.2 |
This summary was machine generated October 31 at 14:13 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments